A5019099440- Hemophilia Treatment and Research
- Blood Coagulation and Thrombosis Mechanisms
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Platelet Disorders and Treatments
- Hemostasis and retained surgical items
- Blood properties and coagulation
- Chronic Myeloid Leukemia Treatments
- Pharmaceutical studies and practices
- Cancer-related gene regulation
- Protease and Inhibitor Mechanisms
- Hemoglobinopathies and Related Disorders
- Nanoparticle-Based Drug Delivery
- Advancements in Transdermal Drug Delivery
- Biosensors and Analytical Detection
- Lipid Membrane Structure and Behavior
- Trauma, Hemostasis, Coagulopathy, Resuscitation
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Gold and Silver Nanoparticles Synthesis and Applications
- Complement system in diseases
- Potassium and Related Disorders
- Antibiotics Pharmacokinetics and Efficacy
- Blood transfusion and management
- Inhalation and Respiratory Drug Delivery
- Pharmacogenetics and Drug Metabolism
University of Waterloo
2017-2025
Mines Saint-Étienne
2017-2021
Inserm
2018-2019
Université Claude Bernard Lyon 1
2018-2019
Université Jean Monnet
2018
Biomatériaux et Bioingénierie
2017
Georges Friedel Laboratory
2017
Abstract Current methods for therapeutic drug monitoring (TDM) have a long turnaround time as they involve collecting patients' blood samples followed by transferring the to medical laboratories where sample processing and analysis are performed. To enable real‐time minimally invasive TDM, microneedle (MN) biosensor monitor levels of two important antibiotics, vancomycin (VAN) gentamicin (GEN) is developed. The MN composed hydrogel (HMN), an aptamer‐functionalized flexible (Flex) electrode,...
Damoctocog alfa pegol (BAY 94-9027, Jivi®) is an extended half-life recombinant factor (F)VIII replacement, indicated for the treatment of haemophilia A in patients aged ≥12 years. Following introduction damoctocog Canada 2020, there have been no reports on routine clinical effectiveness and satisfaction, when switching from a previous FVIII product Canada.
Gold nanoparticles (AuNPs) are a focus of growing medical research applications due to their unique chemical, electrical and optical properties. Because uncertain toxicity, "green" synthesis methods emerging, using plant extracts improve biological environmental compatibility. Here we explore the biodistribution green AuNPs in mice prepare physiologically-based pharmacokinetic (PBPK) model guide interspecies extrapolation. Monodisperse were synthesized capped with epigallocatechin gallate...
Laboratory reagents impact measured factor activity of extended half-life (EHL) concentrates. Variability in measurements may lead to under or over estimation the pharmacokinetic (PK) parameters, and thus influence clinical dosing decisions. Since 2020, WAPPS-Hemo (www.wapps-hemo.org) has been collecting reagent information when haemophilia centres submit data for PK parameters estimation. To identify pairs concentrates (recombinant FVIII FIX) leading significant discrepancies between...
Real-life data on pharmacokinetics of factor (F) VIII/IX concentrates, especially extended half-life (EHL), concentrates in large cohorts persons with hemophilia are currently lacking.This cross-sectional study aimed to establish reference values for terminal (THL) FVIII/IX according concentrate type, age, blood group and inhibitor history.Data were extracted from the Web-Accessible Population Pharmacokinetics Service database. Groups compared by nonparametric tests. THL was modelled patient...
The total body weight-based dosing strategy currently used in the prophylactic treatment of hemophilia A may not be appropriate for all populations. assumptions that guide are valid overweight and obese populations, resulting overdosing ineffective resource utilization. We explored different weight metrics including lean weight, ideal adjusted to determine an alternative is both safe resource-efficient normal overweight/obese adult patients. Using a validated population pharmacokinetic...
The thrombin generation (TG) assay evaluates haemostatic balance, which is influenced by the levels of many coagulation factors and inhibitors. Our objective was to identify determinant TG in haemophilia A (HA) B (HB) patients compare them those healthy controls. Coagulation factor inhibitor levels, TG, were measured platelet-poor plasma from 40 with HA, 32 HB subjects. Data analysed using multiple regression models. In HA patients, VIII a positive endogenous potential (ETP) peak, whereas...
Fanhdi/Alphanate is a plasma derived factor VIII concentrate used for treating hemophilia A, which there has not been any dedicated model describing its pharmacokinetics (PK). A population PK was developed using data extracted from the Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo) project. WAPPS-Hemo provided individual profiles patients sparse observations as in routine clinical care by centers. Plasma activity measurements and covariate on were database. NONMEM...
Background The thrombin generation ( TG ) assay can assess individual clotting potential. potential is correlated with the patient's bleeding phenotype and varies from one patient to other for same degree of factor VIII or IX deficiency. Objective To define in vitro haemophilic patients target level required normalize their . Patients/Methods Plasmas 20 were spiked increasing levels deficient coagulation parameters measured. relationships between determined by linear regression. normal range...
The use of enhanced half-life (EHL) FVIII has improved the quality prophylaxis in haemophilia A, but with a benefit that may vary from one patient to another. We analysed pharmacokinetic data obtained efmoroctocog alfa (rFVIII-Fc) 114 patients and, 47 cases, compared them those previously measured non-EHL FVIII. vivo recovery (IVR) rFVIII-Fc stage clotting assay (OSA) and chromogenic (CSA) was 2.2 2.8 IU/mL per IU/kg, respectively. median (T1/2 ) 14.5 hours whatever FVIII:C used, variable...
Abstract Introduction Emicizumab is dosed as mg/kg and, according to the label, any unused drug left in vial(s) must be discarded, thereby wasting expensive resources. The aim of this study was use population pharmacokinetics illustrate implications changing dosing interval avoid wastage. Methods We used a previously published emicizumab PopPK model after extending its validation children. simulated PK parameters for labelled regimens and using full vials with infusion frequency varied keep...
Extended half-life (EHL) factor VIII (FVIII) products may decrease the burden of prophylactic treatment in haemophilia A by reducing infusion frequency. However, these still exhibit wide inter-patient variability and benefit from pharmacokinetic (PK) tailoring.Identify limited sampling strategies for rFVIIIFc, an EHL FVIII product, that produce accurate estimates PK parameters relevant troughs.We performed a analysis on simulated populations adults, adolescents, children based published...
Bronchoalveolar lavage (BAL) is a diagnostic procedure which samples the cellular and non-cellular components of pulmonary epithelial surface. The inherent biological noise BAL fluids inhibits their direct mineralogical analysis while currently available particle retrieval protocols are suspected to impose quantitative qualitative bias on studied load. This study presents simple method for near-lossless extraction citrate-capped gold nanoparticles from human at sub-ppm levels enables...
Nonacog alfa, a standard half-life recombinant factor IX (FIX), is used as prophylactic treatment in severe haemophilia B (SHB) patients. Its determined clinical studies involving limited sampling (72 h) was shown to be rather short. In our practice, we suspected that its could have been underestimated.We aimed evaluate nonacog alfa pharmacokinetics real world practice based on FIX levels patients receiving prophylaxis.We retrospectively collected data with SHB prophylaxis from eight centres...
Abstract Introduction Plasminogen deficiency is an ultra rare disease whose patients may develop ligneous lesions if untreated. Prophylactic replacement therapy with plasma derived plasminogen, Ryplazim, efficient in treating and could benefit from pharmacokinetic (PK) tailoring. Aim The objectives of this study are to develop, evaluate integrate into the WAPPS‐Hemo platform a Population PK model supporting prophylactic for deficient patients. Methods modelling evaluations followed same...